Bio-Connect

JAK2 (phospho Tyr1007/1008) antibody

GTX132784
GeneTex
ApplicationsWestern Blot
Product group Antibodies
ReactivityHuman, Mouse
TargetJAK2
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    JAK2 (phospho Tyr1007/1008) antibody
  • Delivery Days Customer
    9
  • Application Supplier Note
    WB: 1:500-1:3000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Applications
    Western Blot
  • Certification
    Research Use Only
  • Clonality
    Polyclonal
  • Concentration
    0.25 mg/ml
  • Conjugate
    Unconjugated
  • Gene ID3717
  • Target name
    JAK2
  • Target description
    Janus kinase 2
  • Target synonyms
    JAK-2; Janus kinase 2 (a protein tyrosine kinase); JTK10; tyrosine-protein kinase JAK2
  • Host
    Rabbit
  • Isotype
    IgG
  • Protein IDO60674
  • Protein Name
    Tyrosine-protein kinase JAK2
  • Scientific Description
    This gene product is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. It has been found to be constituitively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis. [provided by RefSeq]
  • Reactivity
    Human, Mouse
  • Storage Instruction
    -20°C or -80°C,2°C to 8°C
  • UNSPSC
    12352203

References

  • Cisplatin or Doxorubicin Reduces Cell Viability via the PTPIVA3-JAK2-STAT3 Cascade in Hepatocellular Carcinoma.
    Read more
  • Water extract of medicinal ink (WEMI) attenuates lipopolysaccharide-induced NO production of Raw264.7 cells via downregulating JAK2/STAT3-mediated iNOS expression. Lin ZH et al., 2022 Jan 10, J Ethnopharmacol
    Read more
  • Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway. Shen M et al., 2019 Apr 8, J Exp Clin Cancer Res
    Read more